Soumyadeep Chattopadhyay, Rudradeep Hazra, Arijit Mallick, Sakuntala Gayen, Souvik Roy
{"title":"A review exploring the fusion of oncolytic viruses and cancer immunotherapy: An innovative strategy in the realm of cancer treatment.","authors":"Soumyadeep Chattopadhyay, Rudradeep Hazra, Arijit Mallick, Sakuntala Gayen, Souvik Roy","doi":"10.1016/j.bbcan.2024.189110","DOIUrl":null,"url":null,"abstract":"<p><p>Oncolytic viruses (OVs) are increasingly recognized as potent tools in cancer therapy, effectively targeting and eradicating oncogenic conditions while sparing healthy cells. They enhance antitumor immunity by triggering various immune responses throughout the cancer cycle. Genetically engineered OVs swiftly destroy cancerous tissues and activate the immune system by releasing soluble antigens like danger signals and interferons. Their ability to stimulate both innate and adaptive immunity makes them particularly attractive in cancer immunotherapy. Recent advancements involve combining OVs with other immune therapies, yielding promising results. Transgenic OVs, designed to enhance immunostimulation and specifically target cancer cells, further improve immune responses. This review highlights the intrinsic mechanisms of OVs and underscores their synergistic potential with other immunotherapies. It also proposes strategies for optimizing armed OVs to bolster immunity against tumors.</p>","PeriodicalId":93897,"journal":{"name":"Biochimica et biophysica acta. Reviews on cancer","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biochimica et biophysica acta. Reviews on cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.bbcan.2024.189110","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/14 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Oncolytic viruses (OVs) are increasingly recognized as potent tools in cancer therapy, effectively targeting and eradicating oncogenic conditions while sparing healthy cells. They enhance antitumor immunity by triggering various immune responses throughout the cancer cycle. Genetically engineered OVs swiftly destroy cancerous tissues and activate the immune system by releasing soluble antigens like danger signals and interferons. Their ability to stimulate both innate and adaptive immunity makes them particularly attractive in cancer immunotherapy. Recent advancements involve combining OVs with other immune therapies, yielding promising results. Transgenic OVs, designed to enhance immunostimulation and specifically target cancer cells, further improve immune responses. This review highlights the intrinsic mechanisms of OVs and underscores their synergistic potential with other immunotherapies. It also proposes strategies for optimizing armed OVs to bolster immunity against tumors.
人们日益认识到，肿瘤溶解病毒（OV）是治疗癌症的有效工具，它能有效地针对和消除致癌物质，同时保护健康细胞。它们在整个癌症周期中触发各种免疫反应，从而增强抗肿瘤免疫力。基因工程 OV 可迅速摧毁癌组织，并通过释放危险信号和干扰素等可溶性抗原激活免疫系统。它们能够同时刺激先天性免疫和适应性免疫，因此在癌症免疫疗法中特别具有吸引力。最近的进展涉及将 OV 与其他免疫疗法相结合，并取得了可喜的成果。旨在增强免疫刺激和特异性靶向癌细胞的转基因 OV 可进一步改善免疫反应。本综述重点介绍了 OV 的内在机制，并强调了其与其他免疫疗法的协同潜力。它还提出了优化武装 OV 以增强抗肿瘤免疫力的策略。
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
